

[ENZYMATIC TREATMENT OF RETINITIS PIGMENTOSA AND RELEVANT  
PHARMACEUTICAL COMPOSITION THEREFOR IN FORM OF A KIT]  
**ENZYMATIC TREATMENT OF RETINITIS PIGMENTOSIS**

Please amend page 1, paragraph 2, to read as follows:

**[DESCRIPTION]**

Please amend page 1, paragraph 3, to read as follows:

**[Field of the invention]**

**- - FIELD OF THE INVENTION - -**

The present invention [concerns a] relates generally to treatment of medical related conditions and, more particularly, to the treatment of retinitis pigmentos[a]is and the like [by means of enzymes and a pharmaceutical composition in kit form that can be used for this treatment].

Please amend page 1, paragraph 4, to read as follows:

**[Description of the prior art]**

**- - BACKGROUND OF THE INVENTION - -**

Retinitis pigmentos[a]is is a disease of the retina [that presents] having many different pathological manifestations[:]. Notably, I[i]t [may] can not only [bring about a] cause restriction of the field of vision [and create], but also increasing difficulty in

adapting to the dark and to penumbra, when it affects the peripheral zones of the retina, which accommodate [the] a greater part of the rod cells that [render possible] make vision in penumbra and [the] perception of movement in the lateral zones possible[, or]. Alternatively or concurrently, it may lead to loss of central vision when the cone cells are the ones to undergo modification. The rate [of progress of] at which the illness progresses varies from one [subject] patient to another. [As a general rule] Generally speaking, however, retinitis pigmentos[a]is is an insidious disease that most often manifests itself in youth, [but often also affects] especially children [and acts in an insidious manner].

Please amend from after paragraph 4 on page 1 to before the first full paragraph on page 2 to read as follows:

The cause(s) [responsible for] of this infirmity are [as yet] presently unknown and, consequently, there [does] is not yet [exist] a[ny] cure [for those affected by it]. The [sole certain] only information known for certain about the disease, that is at the disposal of experts [regards the], concerns a possible genetic origin of retinitis pigmentos[a]is, which is [in part] believed to be transmitted, in part, by heredity from generation to generation, following mechanisms that are known generally to geneticists. [The greater part of the] Most forms of retinitis pigmentos[a]is are hereditary and three transmission modalities have [so far] been identified thus far: dominantly autosomal, recessively autosomal and bound up with sex (X-linked).

Please amend page 4, first full paragraph, to read as follows:

**-- OBJECTS AND SUMMARY OF THE INVENTION --**

[The] Accordingly, it is an object of the present invention [is] to provide a pharmacological composition in the form of a kit [form that will permit] for effective and efficient treatment of retinitis pigmentos[a]is [to be efficiently treated].

Please amend page 5, second full paragraph, to read as follows:

**-- DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS --**

There is provided a specific, illustrative enzymatic treatment of retinitis pigmentosis and a pharmaceutical composition for treating the same in kit form, according to various aspects of the present invention. More particularly, according to one embodiment of the present invention, the enzymes employed are glutathione peroxidase (hereinafter referred to as Enzyme A), prolidase (hereinafter referred to as Enzyme B), glucose-6-phosphate-dehydrogenase (hereinafter referred to as Enzyme C), which are administered in accordance with a time sequence and modalities to be [further specified] described in greater detail [herein]below.

Please insert the following new paragraph after the paragraph ending at the top of page 9: